Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115578) titled 'TAS-102 plus Fruquintinib or TAS-102 plus Fruquintinib in combination with Chidamide and Serplulimab as third-line and beyond treatment for metastatic colorectal cancer:A multicenter, randomized, two-arm clinical trial' on Dec. 29, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First Affiliated Hospital of Soochow University
Condition:
colorectal cancer
Intervention:
Group A:TAS-102 plus Fruquintinib in combination with Chidamide and Serplulimab
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-01-01
Target Sample Size: Group A:32;Group B...